Correction: Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma

Rusdina Bte Ladju; Devis Pascut; Muhammad Nasrum Massi; Claudio Tiribelli; Caecilia H.C. Sukowati

doi:10.18632/oncotarget.24572

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma

PDF | How to cite

Oncotarget. 2018; 9:13101-13101. https://doi.org/10.18632/oncotarget.24572

Metrics: PDF 1785 views | ?

Rusdina Bte Ladju^1,2, Devis Pascut¹, Muhammad Nasrum Massi², Claudio Tiribelli¹ and Caecilia H.C. Sukowati¹

¹ Fondazione Italiana Fegato, AREA Science Park Basovizza, Trieste, Italy
² Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Published: February 26, 2018

This article has been corrected: The updated Acknowledgments information is provided below:

ACKNOWLEDGMENTS

RBL is supported by fellowships from the Lembaga Pengelola Dana Pendidikan (LPDP) of the Indonesian Ministry of Monetary, DP by NECTE project of PAR-FSC_2007-13 decree n° 3984/LAVFOR.ISTR/2014 Friuli Venezia Giulia, CHCS fellowship was partially supported by grant NIH U01AA020821. This work was supported by in-house grant from the Fondazione Italiana Fegato, Trieste, Italy, and the Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.

Original article: Oncotarget. 2018; 9:2951-2961. DOI: https://doi.org/10.18632/oncotarget.23359.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24572

Publication Alerts

Post-Publication Promotion

Corrections:

Correction: Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma